Bedrijfsoverzicht
Heartflow, Inc. is a medical technology enterprise dedicated to delivering non-invasive diagnostic and management solutions for coronary artery diseases across the United States and globally. The company leverages its HeartFlow Platform, which utilizes artificial intelligence and computational fluid dynamics to generate personalized three-dimensional models of a patient's heart from a single scan, thereby enhancing clinical decision-making. Operating within the Healthcare sector and specifically the Health Information Services industry, the firm focuses on transforming cardiovascular care through advanced data analytics and modeling. With a market capitalization of $2.31 billion, an annual revenue of $176.03 million, and an employee base of 843 individuals, the company demonstrates significant scale within its niche. These valuation and revenue figures indicate that the market assigns substantial value to the firm's proprietary technology platform and its established position in the non-invasive diagnostics landscape, reflecting confidence in its ability to capture a meaningful share of the growing cardiovascular care market.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $176.03 million, while simultaneously recording a net income of -$116,791,000 and an EBITDA of -$62,626,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by research, development, and general administrative costs, significantly exceed the gross profits generated from sales. The free cash flow stands at -$30,882,376, which indicates that the company is currently burning cash rather than generating liquidity, suggesting that financial flexibility is constrained and dependent on capital markets or existing cash reserves to fund operations. Despite the negative earnings, the gross margin is reported at 76.8%, indicating that the cost of goods sold is relatively low compared to revenue, while the operating margin of -36.1% and profit margin of -66.3% highlight that high operational and administrative expenses are eroding profitability at an aggressive rate. On the balance sheet, the firm holds $176.79 million in cash against $22.05 million in debt, resulting in a debt-to-equity ratio of 7.34, which characterizes a leveraged balance sheet where equity is used to support a relatively small debt load, yet the high leverage ratio combined with losses raises solvency concerns. The current ratio of 5.20 suggests strong short-term liquidity, as the company possesses more than five times the current assets necessary to cover its current liabilities, providing a buffer to manage short-term obligations despite the operating losses. Furthermore, the return on equity is -111.4% and the return on assets is -16.7%, metrics that reveal that management's effectiveness in generating profits from shareholders' equity and total assets is currently negative, a common characteristic for high-growth biotech or medtech firms in the early stages of commercialization or expansion.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to negative net income, while the forward P/E is -89.77, implying that the market is pricing the stock based on future earnings expectations that are currently undefined or negative, rather than current profitability. The price-to-book ratio stands at 7.65, indicating that the market values the company at a significant premium over its book value, likely reflecting the intangible value of the proprietary HeartFlow Platform and its intellectual property. The price-to-sales ratio is 13.13 and the EV/EBITDA is -34.43, suggesting that traditional valuation metrics based on earnings are not applicable, and investors are relying on sales multiples to value the potential growth trajectory of the revenue base. The stock has a 52-week high of $41.22 and a 52-week low of $20.13, meaning the current trading price fluctuates within this range, though the exact current price is not provided, the wide spread indicates high volatility in the secondary market. The beta value is N/A, which means there is no available historical data to quantify the stock's price volatility relative to the broader market, leaving the risk profile regarding systemic market movements undefined in this dataset. These valuation metrics collectively portray a high-risk, high-reward profile typical of companies with negative earnings but strong revenue growth, where investors are betting on future profitability rather than current financial performance.
Growth & Income
The revenue growth year-over-year is 40.5%, whereas the earnings growth year-over-year is N/A, indicating that while top-line sales are expanding rapidly, the company is not yet profitable enough to calculate meaningful earnings growth rates. Since the earnings growth metric is unavailable due to negative net income, the rapid revenue expansion implies that the company is in a growth phase where reinvestment of capital is prioritized over immediate profit generation, rather than earnings growing faster than revenue. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. As a non-dividend payer, Heartflow, Inc. reinvests all of its available earnings and cash flow back into the business to fund operations, research, and development necessary to sustain its high growth rates and expand its market presence. The overall growth and income profile is characterized by exceptional revenue expansion coupled with a complete absence of dividend income, reflecting a strategy focused on long-term capital appreciation through business scaling rather than current cash distribution to investors.